A retrospective observational study conducted at Tampere University Hospital Heart Hospital in Finland has evaluated the economic and clinical implications of a lifecycle-based payment model for transcatheter aortic valve replacement (TAVR). The research, published in Cost Effectiveness and Resource Allocation, compares this novel reimbursement structure against the traditional lump-sum model used in public healthcare.
The cohort was divided into two groups: 92 patients treated under the novel lifecycle model and 132 patients treated under the standard lump-sum reimbursement model. To ensure a rigorous comparison, the researchers addressed baseline imbalances between the groups using Inverse Probability of Treatment Weighting (IPTW).
The financial analysis focused on total healthcare costs during the initial two-year period and projected costs over a ten-year horizon. To estimate long-term expenses, the team utilized a discounted cash flow model with discount rates of 0%, 3%, 5%, and 7%. A critical component of this projection was the refinement of survival probabilities. The researchers recalculated these probabilities using real-world Kaplan-Meier data and Gompertz extrapolation, drawing from a broader institutional registry cohort of 1,782 patients treated between 2014 and 2023. This approach allowed the team to update the assumptions of the pilot model with more robust, long-term data.
In the short term, the lifecycle-based payment model demonstrated significant budgetary advantages. Over the first four years, the model generated early savings of approximately €2.7 million compared to the lump-sum model.
However, the economic landscape shifted when the analysis extended to a ten-year horizon. The discounted cumulative costs under the lifecycle model were found to be 5.9% higher than those under the lump-sum model. On an individual level, the disparity was even more pronounced, with ten-year discounted costs ranging from 30% to 51% higher across different risk strata. This divergence highlights the long-term financial implications of the payment model, suggesting that while it offers short-term relief, it may impose a greater burden on the healthcare system over the decade following the procedure.
The primary driver of this cost divergence was the survival rates of the patients. The actual survival rates exceeded the estimates set in the initial lifecycle model. As patients lived longer than predicted, the lifecycle payments continued beyond the breakeven point. This breakeven point was defined as the time at which 62% to 72% of the implants remained functional. Because the payments were tied to the duration of the valve’s function and the patient’s survival, the extended life expectancy resulted in a higher total payout for the healthcare system compared to the fixed cost of the lump-sum model.
Clinically, the outcomes remained similar across both cohorts, indicating that the payment model did not compromise patient care. The similarity in these clinical endpoints suggests that the financial restructuring of the payment model did not adversely affect the immediate or short-term health of the patients.
The study concludes that a lifecycle-based payment model for TAVR is feasible within a publicly funded healthcare system and provides early budgetary benefits. However, the research also warns that over a ten-year horizon, this model can incur higher cumulative costs compared to lump-sum reimbursement. To enhance the economic impact and avoid long-term cost overruns, the authors recommend that lifecycle payments should be dynamically adjusted based on real-world data and clinical outcomes.
Subject of Research: Economic and clinical outcomes of a lifecycle-based payment model for transcatheter aortic valve replacement in Finnish public healthcare.
Article Title: Lifecycle-based payment model for transcatheter aortic valve replacement: a retrospective observational study from finnish public healthcare
Article References: Waris, O., Eskola, M., Leskelä, R.-L., Hulkkonen, J., Haukilahti, A., & Torkki, P. (2026). Lifecycle-based payment model for transcatheter aortic valve replacement: a retrospective observational study from finnish public healthcare. Cost Effectiveness and Resource Allocation. https://doi.org/10.1186/s12962-026-00816-y
Image Credits: AI Generated
DOI: 10.1186/s12962-026-00816-y
Keywords: TAVR, Healthcare Economics, Payment Models, Finnish Healthcare, Retrospective Study, Cost Effectiveness, Valve Durability, Public Health Policy, Lifecycle-based, payment, model, transcatheter
Tags: cost-effectivenessFinnish Healthcarehealthcare economicsLifecycle-basedmodelpaymentPayment Modelspublic health policyRetrospective studyTAVRtranscatheterValve Durability
